Erasca, Inc. Effective Income Tax Rate Reconciliation, Other Adjustments, Percent
Erasca, Inc. (ERAS) reported Effective Income Tax Rate Reconciliation, Other Adjustments, Percent of -0.60% for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-20.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments · last filed 2025-03-20
- Erasca, Inc. effective income tax rate reconciliation, other adjustments, percent for fiscal 2024 was -0.60%.
- Erasca, Inc. effective income tax rate reconciliation, other adjustments, percent for fiscal 2023 was -3.10%.
- Erasca, Inc. effective income tax rate reconciliation, other adjustments, percent for fiscal 2022 was -0.80%.
- Erasca, Inc. effective income tax rate reconciliation, other adjustments, percent for fiscal 2021 was -0.60%, a 700.00% decline from fiscal 2020.
| Period end | Effective Income Tax Rate Reconciliation, Other Adjustments, Percent 12 month |
|---|---|
| 2024-12-31 | -0.60% 10-K · filed 2025-03-20 |
| 2023-12-31 | -3.10% 10-K · filed 2025-03-20 |
| 2022-12-31 | -0.80% 10-K · filed 2024-03-27 |
| 2021-12-31 | -0.60% 10-K · filed 2023-03-23 |
| 2020-12-31 | 0.10% 10-K · filed 2022-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |